Bora Pharmaceuticals Completes $122.5M Acquisition of MacroGenics' Rockville Manufacturing Operations

Bora Pharmaceuticals Co., Ltd. announced today the completion of its acquisition of MacroGenics' GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and a warehousing center in Frederick, Maryland, for $122.5 million. The transaction, executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO Service Agreement with MacroGenics.

With this acquisition, Bora Biologics now operates 20,000 liters of single-use bioreactor drug substance manufacturing capacity across two US sites: Rockville and San Diego, California, plus a development facility in Zhubei, Taiwan. Bobby Sheng, Chairman and CEO of Bora Group, stated, "This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply. As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure."

The Rockville facility adds to Bora Biologics' track record of over 120 completed GMP batches and support for more than four active commercial programs, supplying markets including the US, EU, Japan, Canada, and the UK. The combined US network has undergone five FDA inspections, including two at Rockville and one PMDA review in 2025, all with clean results. The platform has supported more than 33 biologics and 15 biosimilars, providing a manufacturing base that reduces offshore dependency.

Bora Group plans to integrate its US drug substance capabilities with existing sterile drug product capabilities over the next 12 to 18 months, aiming to offer a seamless development-through-commercial biologics solution. For more information about Bora, visit https://www.bora-corp.com or https://www.boracdmo.com.

This acquisition marks a significant step in Bora's strategy to expand its biologics CDMO franchise and meet growing demand for US-based manufacturing capacity. The deal underscores the importance of domestic production infrastructure amid evolving regulatory and supply chain landscapes.